NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Insider Sells $390,450.00 in Stock

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) insider Jin-Long Chen sold 15,000 shares of the company’s stock in a transaction on Monday, September 13th. The stock was sold at an average price of $26.03, for a total transaction of $390,450.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Jin-Long Chen also recently made the following trade(s):

  • On Monday, August 9th, Jin-Long Chen sold 15,000 shares of NGM Biopharmaceuticals stock. The stock was sold at an average price of $24.46, for a total transaction of $366,900.00.

Shares of NGM stock traded down $0.02 on Tuesday, hitting $26.17. 242,570 shares of the stock traded hands, compared to its average volume of 353,664. The firm’s 50-day moving average price is $21.93 and its two-hundred day moving average price is $23.69. NGM Biopharmaceuticals, Inc. has a twelve month low of $14.90 and a twelve month high of $32.12. The stock has a market capitalization of $2.02 billion, a PE ratio of -15.67 and a beta of 2.02.

NGM Biopharmaceuticals (NASDAQ:NGM) last released its earnings results on Thursday, August 5th. The company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.13). NGM Biopharmaceuticals had a negative return on equity of 36.71% and a negative net margin of 149.51%. The firm had revenue of $16.77 million for the quarter, compared to analysts’ expectations of $22.08 million. As a group, equities research analysts expect that NGM Biopharmaceuticals, Inc. will post -1.64 EPS for the current fiscal year.

NGM has been the subject of several analyst reports. Stifel Nicolaus decreased their price objective on shares of NGM Biopharmaceuticals from $43.00 to $22.00 and set a “buy” rating for the company in a research note on Monday, May 24th. B. Riley lifted their price objective on shares of NGM Biopharmaceuticals from $32.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, September 7th. Zacks Investment Research cut shares of NGM Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 13th. Piper Sandler boosted their price objective on shares of NGM Biopharmaceuticals from $20.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, August 6th. Finally, Cowen upped their target price on shares of NGM Biopharmaceuticals from $20.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, August 9th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, NGM Biopharmaceuticals has a consensus rating of “Buy” and a consensus price target of $34.55.

Several hedge funds and other institutional investors have recently modified their holdings of NGM. Wells Fargo & Company MN increased its position in shares of NGM Biopharmaceuticals by 174.2% in the second quarter. Wells Fargo & Company MN now owns 43,332 shares of the company’s stock valued at $854,000 after buying an additional 27,531 shares in the last quarter. Metropolitan Life Insurance Co NY grew its holdings in NGM Biopharmaceuticals by 115,612.5% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 9,257 shares of the company’s stock valued at $183,000 after buying an additional 9,249 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in NGM Biopharmaceuticals by 14.3% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 433,858 shares of the company’s stock valued at $8,556,000 after buying an additional 54,395 shares during the period. BVF Inc. IL purchased a new stake in NGM Biopharmaceuticals in the 2nd quarter valued at about $18,833,000. Finally, Boxer Capital LLC acquired a new position in shares of NGM Biopharmaceuticals in the 2nd quarter valued at about $9,860,000. 55.72% of the stock is owned by hedge funds and other institutional investors.

About NGM Biopharmaceuticals

NGM Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its lead product candidate, aldafermin, is designed for the treatment of patients with non-alcoholic steatohepatitis, with liver fibrosis stage 2, 3, or 4.

See Also: Bond

Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.